<DOC>
	<DOCNO>NCT00842790</DOCNO>
	<brief_summary>The goal study impact functional MRI CT evaluation change tumor vessel induce anti-angiogenic treatment patient metastatic RCC . The hypothesis good responder poor responder different response induce anti-angiogenic treatment , detection thesis change functional imaging improve therapeutic management . Functional CT MRI perform 200 patient begin antiangiogenic treatment , 7 day every 6 week tumor progression ( define RECIST criterion ) . Perfusion diffusion parameter measure use dedicate software .</brief_summary>
	<brief_title>Impact Predicting Anti-angiogenic Response mRCC Using Functional Imaging</brief_title>
	<detailed_description>The aim evaluate capacity functional CT functional MRI measure reliable biomarkers capable evaluate efficacy anti-angiogenic treatment . Patient method - Patients 200 patient metastatic RCC enrol study . Patients recruit oncologist image acquire radiologist . Patients follow tumor progression ( defined RECIST ) 2 year follow inclusion progression . - Imaging data acquisition Morphological functional imaging obtain begin anti-angiogenic treatment , 7Â±2 day every 6 week tumor progression . Progression define follow RECIST criterion . - CT examination two part : first one dynamic acquisition 3 min ( use low kV ) focus `` functional target lesion '' bolus injection contrast agent functional analysis , second one morphologic acquisition chest , abdomen pelvis RECIST evaluation . - MRI examination two part : first one diffusion weight sequence focus functional target one imaged CT , second one dynamic acquisition use T1 weight gradient echo sequence le 4 sampling time 5min follow bolus injection contrast agent . - Imaging data analysis The examination anonymized transferred workstation processing . Images process two independent reader . Diffusion coefficient map obtain use linear regression . The microvascular parametric map yield tissue blood flow , tissue blood volume , mean transit time , permeability surface area product tissue interstitial volume calculate CT MRI dynamic series use proprietary software mean compartmental model arterial input function ( AIF ) . Mean parameter record different region interest ( ROI ) tumor ( whole tumor , periphery , center ) . Morphological CT image analyze follow RECIST criterion . -Statistical analysis The functional parameter analyze inter-observer reproducibility . The correlation parameter obtain use functional CT functional MRI test . Patients classify good responder poor responder accord RECIST follow-up . The correlation baseline functional parameter RECIST response test evaluate usefulness baseline parameter predictor response . The correlation parameter 's change treatment compare baseline value test evaluate efficacy parameter detect response anti-angiogenic drug . The precocity detection response use parameter variation also test . Finally , economical impact use microvascular parameter biomarkers treatment efficacy test .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Angiogenesis Inhibitors</mesh_term>
	<criteria>metastatic RCC without previous recent antiangiogenic treatment severe renal insufficiency allergy contrast agent pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>February 2009</verification_date>
	<keyword>Carcinoma , Renal Cell [ C04.557.470.200.025.390 ]</keyword>
	<keyword>Angiogenesis Inhibitors [ D27.505.954.248.025 ]</keyword>
	<keyword>Tomography Scanners , X-Ray Computed [ E07.913 ]</keyword>
	<keyword>Magnetic Resonance Imaging [ E01.370.350.825.500 ]</keyword>
	<keyword>Diffusion Magnetic Resonance Imaging [ E01.370.350.825.500.150 ]</keyword>
	<keyword>Perfusion [ E05.680 ]</keyword>
</DOC>